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NERVE GROWTH FACTOR: BASIC FINDINGS AND CLINICAL TRIALS 
Luigi Aloe and Alessandra Micera 
Institute of Neurobiology, CNR, Rome, Italy 
The nerve growth factor is the first-discovered and best-characterized member of the family ofneurotrophins. In the introduction 
of this article we present a briefbiographic view of past andpresent studies of Rita Levi-Montalcini on nerve growth factor: Further, 
the article focuses onpleiotropic activities of nerve growth factor, exerting on various cell types, including cells of nervous, immune 
and endocrine system. Implications of these actions of nerve growth factor in the pathogenesis of neurological diseases, 
autoimmune-inflammatory diseases, allergic diseases, lymphoproliferative diseases, atherosclerotic cardiovascular disease, and 
neurotrophic corneal ulcers are outlined. Biomed Rev 1999; 10: 3-14. 
INTRODUCTION 
Rita Levi-Montalcini received her medical degree from the 
Faculty of Medicine at the University of Turin, Italy, in 1936. 
In the early postgraduate years, first at the University of Turin 
with Professor Giuseppe Levi and then at home in spite of 
severe personal restrictions and difficulties due to racial dis- 
crimination during World War II, she carried out studies on 
the neurogenesis of the cervical and thoracic ganglia of chick 
that takes place during prenatal development. The results of 
these studies came to the attention of Viktor Hamburger, a 
leading scientist at Washington University of St. Louis, MO, 
USA, who invited her to St Louis to continue these studies 
and to characterise the effect of wing or limb extirpation on 
the development of motor and sensory neurons of chick em- 
bryos. This invitation marked the beginning of a long and fruit- 
ful scientific collaboration between Levi-Montalcini and 
Hamburger and led to the discovery of the nerve growth fac- 
tor (NGF). In the following years, she studied the mechanisms 
of cell migration and neuronal differentiation in the central 
nervous system (CNS) of developing birds. The results she 
obtained on transitional morphology and on cell survival or 
death occurring during nervous system development most 
probably represent the first and best documented contribu- 
tion to the knowledge in the f ield  of experimental 
neuroembryology of what is now more correctly termed 
apoptosis or programmed cell death. 
The NGF story started in 1949 when V. Hamburger showed 
Levi-Montalcini the results of one of his postgraduate students, 
Elmer Bueker, who observed that after the implantation of a small 
fragment of amalignant mouse tumor into the body wall of 3-day 
chick embryos, sensory fibres invaded the mouse tumor. 
Bueker hypothesised that this effect was due to the fact that the 
rapidly expanding tumor offered the possibility to sensory 
fibres to branch in a much larger field than the embryonic tissues 
replaced by the neoplastic cells. This hypothesis did not 
convince Rita Levi-Montalcini, who hypothesized that the 
mouse sarcoma tissues 180 and 37, when transplanted into a 
chick embryo, produced and released a diffusible agent that 
stimulated growth and the differentiation of developing nerve 
cells. Using in vitro methodologies, she demonstrated that 
these tumor tissues produced and released a molecule that was 
able to stimulate neurite outgrowth of sensory and sympathetic 
neurons. In 1952, she gave this substance the name of nerve 
  
Received 15 July 1999 and accepted 22 September 1999. 
Correspondence and reprint requests to Dr Luigi Aloe, Institute of Neurobiology, CNR, Viale Marx 15-43,1-00137, Rome, Italy. 
Tel: 39 06 8682 592, Fax: 3906 8609 0370, E-mail: aloe@in.rm.cni-.it 
  
  
growth factor. In the following years, in collaboration with 
Stanley Cohen, cowinner of the Nobel Prize in 1986, Levi- 
Montalcini identified in a protein fraction the agent released 
by the tumor that promoted the effect on embryonic sensory 
and sympathetic ganglia. These studies led to the discovered 
that NGF was stored in snake venom and in the mouse submax- 
illary salivary gland and that this gland produced the largest 
available source of NGF. This latter finding not only made a 
better biochemical characterisation of NGF possible, but also 
that of its biological activities on neonatal and adult mamma- 
lians and its purification. 
During the early 1950's, Levi-Montalcini, Professor at the 
Department of Zoology at the Washington University in St 
Louis, intensified in vivo and in vitro studies of NGF on small 
rodents, while first S. Cohen and later P. U. Angeletti investi- 
gated the chemical and biochemical properties of NGF and both 
devised a methodology of purifying large quantities of NGF 
from both the snake venom and the mouse salivary gland. The 
availability of large amounts of NGFin the mouse salivary gland 
provided an additional opportunity to carry out numerous and 
collaborative in vivo studies and to investigate the structural, 
biochemical and pharmacological action of NGF on sympathetic 
and sensory nerve cells. Moreover, the large amounts of puri- 
fied NGF also led to the possibility of producing anti-NGF 
antibodies and of further characterising the effects of NGF on 
the development of the peripheral nervous system (PNS) by 
injecting this antibody into newborn rodents. The immuno- 
depri vation of NGF through exogenous administration of NGF- 
antibodies to these rodents and the observation that inhibition 
of circulating NGF levels results in death of NGF-target cells 
described in the late 1960's, became known as immunosym- 
pathectomy. In 1961, Levi-Montalcini established a small neu- 
robiological unit in Rome, first at the Superior Health Institute 
and in 1970, a larger group at the National Research Council, 
where she became director of the newly formed Institute of Cell 
Biology, while in 1986 she founded the Institute of Neurobiol- 
ogy. 
The first time one of us (LA) met Rita Levi-Montalcini was in 
1968 at the Superior Health Institute during her three months 
working visit in Rome, when I was working on the structural 
organisation of the epidermis of the insect Locusta migratoria 
and on Periplaneta americana. I spent the first four years of 
my scientific experience with Levi-Montalcini working on the 
development of the PNS and CNS of cockroaches and on the 
identification of molecules endowed with neurite growth-pro- 
moting activity on isolated nerve cells of the same or other 
insects. After two-three years of intense studies on cockroach 
neurogenesis, we were very close to the identification of the 
biological mediators present in the foregut of Periplaneta 
americana. Because, the quantity of tissue storing this mol- 
ecule was very small and recombinant methods were not yet 
available, Levi-Montalcini decided to give up to idea of isolating 
and purifying this unknown invertebrate neurotrophic factor. 
Looking back, the scientific years spent working on the insect 
nervous system can be considered an original contribution to 
the field of invertebrate neurobiology. Surprisingly, these find- 
ings passed almost unnoticed by most of the scientific commu- 
nity. 
After 1972, Levi-Montalcini returned to NGF studies. The 
first approach to the renewed interest in this neurotrophin was 
the study of NGF on chemical and surgical axotomized pe- 
ripheral neurons. Eugene Gene Johnson, a young pharmacolo- 
gist working at Washington University Medical School in St. 
Louis, MO, USA, joined our group and was introduced to the 
NGF field. These collaborative studies produced the first 
consistent evidence that NGF can prevent injury or even death 
of peripheral neurons exposed to sympatholitic drugs. During 
these same years, numerous other groups working in the USA 
and in Europe showed great scientific interest in NGF studies. 
The increased attention to this molecule brought to light 
original findings regarding its spectrum of action on both the 
developing and the adult CNS, as well as on cells of the 
endocrine and immune system. Meanwhile, other investiga- 
tions led to the identification of NGF receptors (NGFR), 
protein sequences, gene localisation and to the discovery of a 
new class of neurotrophins belonging to the NGF families, as 
well as to a variety of approaches to test the potential clinical 
use of NGF (see other articles in this volume of Biomedical 
Reviews). 
In 1977, Levi-Montalcini published the first indication that 
NGF acts on cells of nonneuronal origin. Subsequently, other 
investigators confirmed and extended this observation and 
provided additional evidence that other cells of the immune 
system are receptive to the action of NGF. More recent 
studies carried out by Levi-Montalcini's group demonstrated 
that NGF is also involved in the regulation of memory B cells 
and that NGF plays an equally important role in the neuronal 
cell population of the CNS controlling the activation of the 
neuroendocrine axis. Other studies carried out in this same 
Institute showed that NGF is also involved in neuroendocrine 
responses, as revealed by findings that the circulating and 
brain NGF levels undergoes significant changes following 
aggressive behavior and in states of emotional anxiety. These 
findings lead to the hypothesis that NGF might be implicated 
in homeostatic interaction and in the pathogenesis of autoim- 
mune inflammatory disorders. In the last ten years murine and 
recombinant NGF received clinical attention from neurolo- 
gists who began to utilize NGF and other neurotrophins to 
induce recovery from neuropathies of the CNS and PNS. 
Additionally, a collaborative investigation between Institute 
of Neurobiology, the University of Rome, Tor Vergata, and 
the division of Ophthalmology, Hospital of Venice also pro- 
vided a clear clinical evidence that NGF can be used in human 
neurotrophic corneal ulcers. 
THE NGF DISCOVERY 
The NGF was discovered in the early 1950's for its properties 
of stimulating growth and differentiation of peripheral sen- 
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sory and sympathetic neurons (1,2). It represents the first 
isolated and best-characterized member of a growing family 
of neurotrophins, which includes brain-derived neurotrophic 
factor and neurotrophins 3-5 (3). In recent years, numerous 
studies have provided evidence that the effects of NGF are not 
limited to the PNS (4,5) but it also act on cells of the CNS and 
on cells of the endocrine and immune systems (6). NGF is 
synthesized and released by a variety of nonneuronal and 
neuronal cells, though the largest amount of this factor is 
produced in the salivary gland (SG) of adult male mice which 
still is considered the best available source of NGF. NGF is 
also produced by guinea pig prostate and human skin (1,7,8; 9, 
this volume of Biomedical Reviews). The NGF isolated and 
purified from male mice SG (2.5S) is a dimer of two identical 
subunits linked together by noncovalent bonds and with a 
molecular weight of about 26 kD (10). The amino acid se- 
quence and primary structure of this neurotrophin has been 
characterized (11) and indicates that NGF is a highly con- 
served molecule that shares a great homology within different 
species (12). Molecular studies have revealed that the human 
gene for NGF is located on the proximal short arm of chromo- 
some 1 (13,14). 
The levels of NGF not only change with age, but also during 
neuroendocrine dysregulations (15-18), following neurological 
insults (19-20) and during autoimmune and allergic diseases (21 - 
26). The elevated levels of NGF are often associated with an 
increase of proinflammatory cytokines, particularly, interleukin- 
1 beta (IL-1 p1) and tumor necrosis factor-alpha (TNF-cc) (27-30). 
MERVE GROWTH FACTOR AMD THE NERVOUS SYSTEM 
During development, NGF is known to promote differentiation, 
growth, and survival of central and PNS neurons (1,5,6). These 
biological activities are mediated by the NGF binding to two 
receptors: TrkA, a high-affinity receptor tyrosine kinase, and 
p75NGFR, a low-affinity receptor which can also bind the other 
neurotrophins (p75NTR) (31-33). In the PNS during postnatal and 
adult life, one key effect of NGF is to stimulate neurite regenera- 
tion of injured nerve cells, regulate synthesis and release of 
neurotransmitters and neuropeptides (34,35), modulate periph- 
eral pain responses (36,37), and is involved in peripheral inflam- 
matory responses (38-40). In the CNS, the highest amounts of 
NGF are produced in the cortex and in the hippocampus which 
are the main target areas for cholinergic neurons localized in the 
nucleus basalis magnocellularis and medial septum, respec- 
tively (5,6,41 -43). Administration of NGF into the brain prevents 
the degeneration of lesioned cholinergic neurons, augments the 
activity of nonlesioned cholinergic neurons, and ameliorates 
spatial impairments in aged rats (44,45). Moreover, intracerebral 
implantation of NGF-secreting cell lines has also been shown to 
promote neuronal survival following experimental lesions (46). 
Clinical studies published in the last ten years seem also to 
support the hypothesis that NGF, along with other neuro- 
trophins, may play a pivotal role in human forebrain cholin- 
ergic deficits, including aging and Alzheimer's disease (AD) 
(47-51). 
Since one of the major limitations in the use of NGF in brain 
pathologies is its large molecular size and its difficulty in 
crossing the blood-brain barrier, it was recently suggested for 
its utilization, that NGF could be conjugated to transferrin 
receptor antibody (52), or alternatively to use pharmacological 
agents which act on brain NGF-producing cells (53, also this 
volume of Biomedical Reviews). There is also the possibility 
that drugs, which stimulate the release of NGF produced by 
resident cells, including mast cells (MC), may be potential useful 
to enhance the level of NGF in pathologies associated with the 
low availability of NGF. This latter aspect is currently under 
investigation in our laboratory. 
Recent studies have also shown that NGF is present in the 
hypothalamus (54-57) and participate in stress responses 
(15,17,18) and in neuroendrocrine functions (58,59). 
NGF IN NEUROIMMUNE AMD IMMUNE RESPONSES 
The first evidence that NGF acts on cells of the immune 
system lineage was published 1977 by Aloe and Levi- 
Montalcini who showed that injection of NGF in newborn rats 
caused an increase in the number and size of MC (60). This 
observation was confirmed and extended in later years by 
showing that NGF-primed spleen cells, transplanted into the 
brain ventricles of donor rats, differentiate into MC (61). MC 
express NGFR (61-64) and in vitro administration of NGF 
induces MC degranulation and histamine release (61,62,64- 
66) increasing their survival (63, 66). An important piece of 
evidence indicating a role of NGF in immune cell survival was 
published a few years ago. It was shown that NGF prevents 
programmed cell death (apoptosis) and promotes cell differ- 
entiation in developing chick bursal cells (67,68). Recently, 
it was reported that NGF could support long term growth of 
human haemopoietic cells (69). NGF has a dose dependent 
influence on the survival of mature, differentiated cells of 
myeloid lineage such as eosinophils (70) and neutrophils (71) 
and in these latter cells, the viability sustaining activity of 
NGF has been attributed to its effect on apoptosis (72). More 
recently it has been reported that NGF is a survival factor for 
memory B cells, both in humans and mice (73). NGF is 
endogenously produced by B cells and the treatment with 
neutralizing anti-NGF antibodies induced the disappearance 
of bcl-2 protein and massive DNA fragmentation, mainly 
affecting the survival of the IgG or IgA positive cells in vitro 
and in vivo (73). 
Besides these activities, there is ample evidence that the 
NGF-NGFR system is able to exert a wide variety of in vitro 
effects on immune cells. NGF acts as a colony-stimulating fac- 
tor for human and murine myeloid progenitor cells (74,75). It 
affects specifically basophilic differentiation (76), induces me- 
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diator release from basophils, eosinophils and neutrophils 
(71,77,78), acts as a chemoattractant for polymorphonuclear 
leukocytes (79,80), and enhances neutrophil phagocytosis 
(71). Studies on mature lymphoid cells demonstrated that NGF 
has a dose dependent proliferative effect on both B and T cells 
(81,82) and causes differentiation of B cells into immuno- 
globulin-secreting plasma cells (82). NGF stimulates B lym- 
phocytes to produce IgM, IgA, and IgG (82-85) and is also 
able to induce high-affinity interlukin-2 receptors on human 
peripheral blood mononuclear cells (84,86). 
All this in vitro data indicates that NGF is involved in the 
modulation of immune cell development and differentiation. 
This hypothesis is supported by in vivo studies showing NGFR 
expression on stromal and immune cells within lymphoid org- 
ans (87-90). We have demonstrated that the thymus is able to 
produce and store NGF, that thymic cells express both low- and 
high- affinity NGFR, and that these cells produce high levels of 
NGF both in prenatal and early postnatal life (90a). 
The effect of NGF on peripheral lymphocytes may be also 
mediated by centrally produced NGF, since intracerebral injec- 
tion of this molecule induces proliferation of splenocytes (91). 
Data from our laboratory and others indicate that several 
autoimmune inflammatory diseases are characterized by an 
altered concentration of circulating NGF levels (21,26,92). Thus 
NGF is involved in the mechanisms related to regulation of 
immune cell proliferation, differentiation and activation. The 
fact that cytokines are known to affect NGF synthesis (27-30), 
differences in tissue cytokines and NGF expression, either alone 
or in combination, may be functionally correlated in these 
pathologies. In at least one case, however, anti-NGF antibodies 
were shown to prevent the wasting induced by TNF-a in 
transgenic arthritic mice over expressing this cytokine (93). 
TNF-a is produced and secreted by numerous cells including 
MC (94). However, whether the increase in NGF is a cause or a 
result of these immune processes remains to be elucidated. A 
variety of studies in the last fiftheen years have focused their 
attention on the possible functional significance of NGF-MC 
interaction and more recently, MC and TNF-a release. MC are 
immune cells that are predominantly observed in perivascular 
locations in mucosal and serosal tissues (94,95). They are also 
resident within the normal nervous system, and are often 
observed in close apposition to neurones in a variety of periph- 
eral tissues (94,96). MC are classically associated with the 
hypersensitivity reactions involving the interaction of aller- 
gens with cell-fixed IgE (94,96,97). Although their role in ana- 
phylaxis has been largely elucidated, research on these enig- 
matic cells has recently gained great interest after the observa- 
tions that MC respond functionally (via specific receptors) to 
an enormous range of neuroactive compounds including NGF, 
derived from both the CNS and PNS (60,66,98). Considerable 
evidence published by numerous investigators indicated that 
MC and their endogenous products were strongly implicated 
not only in the classical immune processes, but also in neuro- 
physiological and neuropathological events. MC are implicated 
in inflammatory and/or autoimmune diseases, such as multiple 
sclerosis, through the release of biologically active compounds, 
including NGF (96,97,99). Indirect evidence supporting the 
hypothesis of apotential functional role of NGF-MC interaction 
is suggested by recent clinical observations of AD, a neuro- 
pathological disorder which seems to be associated not only 
with severe neurological deficits and loss of cognitive functions 
(41-43,48,49) but also with altered immunological responses 
(100-103). The notion that inflammatory mediators are involved 
in AD was strengthened by observations of patients affected 
by rheumatoid arthritis who undertook a treatment with a 
nonsteroidal antiinflammatory drug over long periods of time, 
and displayed reduced incidence of this disease (101 -103). If one 
considers that NGF (i) exerts powerful activity on basal fore- 
brain cholinergic neurons, (ii) prevents or reduces the neuro- 
logical deficits if administered to AD patients and improves 
some neuropathological alterations and progressive loss of 
cognitive function associated with degeneration of brain neu- 
rons, (Hi) is elevated in inflammatory conditions, and (iv) 
proinflammatory cytokines, such as IL-1 (3 and TNF-a, promote 
NGF synthesis, the possibility exists that NGF released by pro- 
inflammatory cells may be functionally linked to the neuro- 
inflammatory conditions described in AD patients (22,101,102). 
The possibility also exists that proinflammatory compounds 
released by MC following exposure to NGF, or NGF itself, may 
be implicated in promoting or exacerbating the inflammatory 
responses although, this seems unlikely since exogenous ad- 
ministration of NGF in developing or adult rats does not induce 
inflammation (21,104). It would be extremely important, there- 
fore, to investigate whether any correlation exists among the 
distribution and/or activation of brain MC, NGF secretion, and 
AD. 
Recent studies carried out in collaboration with Sergio Bonini 
of the Department of Allergology and Clinical Immunology, 
second University of Naples provided the crucial evidence that 
circulating NGF levels are enhanced in humans with allergic 
diseases (25). These studies revealed that NGF increases in 
patients with asthma, rhinoconjunctivitis, and urticaria-an- 
gioedema as compared to controls, while patients affected with 
more than one allergic diseases express higher NGF values than 
those with a single disease. The fact that NGF levels correlated 
with total IgE antibody liter further support the hypothesis of 
a link between NGF and allergic responses. A key question 
raised by these observations is whether in allergic responses, 
activated MC or other proinflammatory cells produce the pres- 
ence of circulating NGF. Eosinophils are the predominant in- 
flammatory cells of the late phase and chronic development of 
allergic inflammation that along with MC and Th2 cells, play a 
central role in the pathogenesis of allergic diseases. Collabora- 
tive studies with Francesca Levi-Schaffer from the Hebrew 
University of Jerusalem indicate that NGF can induce circulat- 
ing human eosinophils to release important proinflammatory 
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mediators. This release seems not to be necessary linked to a 
cytotoxic effect of NGF on these cells, since no significant 
increase in the mortality rate of eosinophils was observed (70). 
These studies also demonstrated that eosinophils contain 
variable levels of NGF protein and mRNANGF, suggesting that 
eosinophils have the ability to produce and store NGF (105). 
Using an animal model of allergy it has been recently demon- 
strated that allergic airway inflammation in adult rodents is 
accompanied by an enhanced local NGF production (106). To 
gain additional information regarding the role of overespression 
of circulating NGF and allergic responses and better understand 
mechanisms of NGF-MC interaction, we have recently investi- 
gated the effect of highly purified NGF on the behavior of MC 
in nasal epithelia and lungs. 
There is clinical evidence that overly fearful youngsters are 
at risk of later emotional distress and allergic disorders, and 
other clinical observations indicate a close relationship be- 
tween psychological factors and allergy (107). A significant 
number of patients displaying anxious, depressive or stress- 
related behavior seems to suffer more frequently from allergic 
diseases when compared to healthy subjects (107). Because 
psychological factors can cause improvement or worsening of 
the allergic conditions, as well as the release of NGF, one may 
wonder whether a functional link exists between certain psycho- 
socially stressful events, MC activation and NGF release. As 
previously reported the levels of circulating NGF, released 
during stress in male mice are correlated to the number of 
fighting episodes (15,17). In a subsequent study, it became 
evident that the increase of NGF in the bloodstream was not 
simply associated with the expression of aggressive behavior 
because sera of the mice repeatedly experiencing defeat and 
submission contained higher NGF levels than those dominating 
attacking animals (108). Those stimuli of a psychological nature, 
most likely associated with anxiety, also trigger the synthesis 
and release of NGF. This hypothesis is suggested by subse- 
quent studies obtained in humans that anxiety induced by 
alcohol or heroin withdrawal also enhanced blood NGF levels 
(109). Drugs, which induced sedation, lowered the basal amount 
of these factors (110). Though the functional significance of 
elevated levels of NGF in stress-related events remains unclear, 
it is possible the NGF produced and released by MC is involved 
in the protection of NGF target cells from potential toxic 
insults. Thus, MC degranulation and high circulating levels of 
NGF occurring during allergy could function as a general 
alerting signal utilized by the organism in settings of stress 
and anxiety to "prime" the immune system towards external 
noxious perturbation. Altogether, these observations suggest 
that beyond its classical role in allergic mechanisms and 
defense against parasites, MC should be viewed as an impor- 
tant key player in other biological reactions, including 
neuroimmune regulated physiological processes (96,111). 
NGF AND AUTOIMMUNE DISEASES 
Several in vitro and in vivo studies published in the last few 
years have provided clear evidence that numerous cells of the 
immune system not only produce NGF (67,82,112,113), but are 
also receptive to the action of NGF both under normal and 
pathological conditions (45,114,115). The key in vivo 'data 
suggesting a role of NGF on these cells is that certain autoim- 
mune inflammatory diseases are characterized by an activation 
of immunocytes and a significant alteration in the basal NGF 
levels. Alteration of basal NGF levels were found in the synovium 
of patients affected by rheumatic arthritis (22), knee joints of 
pharmacological-induced arthritis in rodents (92), cerebrospi- 
nal fluid of patients affected by multiple sclerosis (23), plasma 
of patients affected by lupus erythematosus (24), and the skin 
of patients with systemic sclerodermia (116). Moreover, studies 
carried out on animal models have shown that in numerous 
autoimmune inflammatory diseases, there is a close correlation 
between the inflammatory conditions and a variation in the 
constitutive level of NGF (25,26,117). Indeed, in mice affected by 
lupus erythematosus, the levels of NGF increase in the spleen, 
kidney and plasma and decrease in the CNS (118). Therefore, a 
relevant question raised by these observations is whether the 
changes of NGF levels found in these autoimmune diseases are 
due to an increase of NGF synthesis, to a low utilization or to an 
altered turnover of this factor by its target cells. In animal models 
of inflammatory diseases, the increase of NGF protein is asso- 
ciated with an increased expression of mRNANGP and NGFR 
(119), making it highly probable that these events are related to 
a functional upregulation of NGF. 
The elevated levels of NGF in some autoimmune diseases (21), 
is also associated with an increase in both brain and synovial 
MC (22,104,120). As indicated above, MC are able to produce 
NGF (112), are receptive to the action of NGF (60,120) and can 
release numerous proinflammatory mediators, allowing the 
possibility that NGF-MC interaction may be associated with 
inflammatory response dysregulations. The fact that other 
forms of homeostatic alterations, such as aggressive behavior, 
stress induced by alcohol or heroin withdrawal, and parasite 
infection also result in an increase of circulating NGF (15,109, 
122), suggests that NGF may be involved in mechanisms corre- 
lated with preventing and repairing possible damage to NGF 
target cells. It has been reported that low levels of or the absen- 
ce of circulating NGF can also characterize certain autoimmune 
diseases and, curiously, by a concomitant increase of NGF 
antibody (123). This apparent contradictory observation may 
be due to the fact that chronic exposure of supranormal amo- 
unts of NGF in the bloodstream can generate production of 
autoantibodies against NGF. In fact, evidence supporting this 
hypothesis was recently obtained in our laboratory in chroni- 
cally-stressed mice (124). It was observed that aggressive 
behavior in mice, which induces a massive discharge of the 
endogenous release of NGF in the bloodstream, leads to the 
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production of NGF autoantibodies and a significant decrease 
of peripheral sympathetic innervation. 
NGF RECEPTORS AS A POTENTIAL MARKER OF IMMUNE 
DISORDERS__________________________ 
Considerable evidence published in the last ten years indi- 
cates that NGF is produced and released by several cells 
belonging to the immune system and that cells of the immune 
system lineage are receptive to the action of NGF. Recent 
studies demonstrated that NGF is produced by bone marrow 
derived stromal cells (69), and that erythroleukemia cells 
express NGFR (125) thus indicating that NGF can influence 
early hematopoiesis. Moreover, detailed immunocytochemi- 
cal analysis carried out on normal and malignant human tis- 
sues indicated that lymphomas, including one classified as a 
malignant lymphomas of B cell type, as well as in Hodgkin's 
diseases, overexpress NGFR (126). Surprisingly, no attempt 
has been made to explore the influence of the pharmacologi- 
cal treatment on NGF circulating levels or on the NGFR 
expression in peripheral cells or in lymphoid tissues in these 
diseases. Using peripheral blood cells of patients affected by 
chronic myeloproliferative disorders, we found that both the 
basal plasma NGF level and the distribution of NGFR in these 
cells undergo changes during the course of the disease. For 
example, we found a significant increase of NGFR expression 
on mononucleated cells from patients affected by chronic 
myelogenous leukemia and an altered plasma concentration 
of NGF (127). This study also showed that drugs, which are 
routinely used in therapy (such as hydroxyurea), influence 
both NGF and NGF receptor. These preliminary observations 
raise the question as to whether either NGF or NGFR may be 
potentially useful as a marker for some differentiative step of 
the haemapoietic stem cells or for the analysis of cell deficits. 
Based on findings obtained with the human neuroblastoma 
cells indicating that the presence or absence of NGFR a 
valuable marker for the clinical outcome of this neurological 
disease (128), the possibility that NGF/receptor expression 
may be of clinical use for establishing a better prognosis 
cannot be excluded. 
MGF IN CARDIOVASCULAR DISEASE 
Because NGF is known to play a crucial role in PNS and in smooth 
muscle innervation, a question we asked as to whether NGF is 
involved in the pathogenesis of atherosclerosis. We recently 
addressed this issue in collaborative studies between George 
Chaldakov, Medical University, Varna, Bulagaria, and the Insti- 
tute of Neurobiology, CNR, Rome, Italy. These studies indicate 
that NGF levels, p75NGFR immunoreacti vity, and MC number 
undergo significant alteration in human atherosclerotic coro- 
nary arteries and surrounding subepicardial adipose tissue, 
suggesting a role of neuroimmune mediators in the process of 
pathogenesis of atherosclerotic cardiovascular disease (129, 
this volume of Biomedical Reviews). 
NGF AMD HEUROTROPHIC OCULAR ULCER 
Corneal healing deficit is the major cause of treatment failure 
and visual impairment in ocular surface pathology. In these 
conditions, a persistent epithelial defect may progress into a 
corneal stromal ulcer, leading to ocular perforation with 
subsequent visual loss (130). Several noninfectious ocular 
and systemic diseases may also lead to corneal epithelial 
damages. Likewise, patients suffering from disorders induced 
by fifth nerve palsy, postviral infections, chemical burns, 
corneal surgery, topical anaesthetic abuse, neurotrophic kerati- 
tis, diabetes, and multiple sclerosis very often display severe 
corneal lesions (131). All these diseases are characterized by 
a deficit of the corneal sensitivity innervation with frequently 
associated progressive corneal damage. Unfortunately, up to 
date, no treatment is available which normalizes these patho- 
logical changes and thus, the final outcome can frequently be 
the loss or severe impairment of visual function. We have 
recently reported that patients affected by corneal ulcer treated 
for 2-6 weeks with topical application of NGF display corneal 
healing beginning two days after exposure to this molecule. 
The effect is not impaired by the severity of corneal ulcer, 
depth of the stroma lesion, or by the clinical history of the 
patients, since the treatment with NGF is equally effective. 
Also, none of the patients with NGF showed systemic or 
ocular side effects during the NGF treatment or during the 
follow up period which lasted for over two years (131,132). 
The restored corneal sensitivity persisted for months after 
NGF treatment was discontinued, suggesting that this factor 
may have provided a long-term benefit to sensory innervation. 
This finding is consistent with the knowledge of the patho- 
physiological role of sensory innervation in corneal wound 
healing. The cornea is virtually a vascular tissue, with the most 
dense innervation in the human body (40 times more than the 
tooth pulp and 400 times more than skin). Thus, any inflamma- 
tory reaction and subsequent healing process undergone is 
highly controlled by this innervation (5). Experimental observa- 
tions confirm that corneal nerve damage induce severe alter- 
ations in the metabolism and vitality of the epithelium, and 
clinical evidence shows that surgical (such as in trigeminal 
manipulation or penetrating keratoplasty) or chemical (such as 
after local anaesthetic abuse) damage of the corneal innervation 
induces an impairment of epithelial healing and the development 
of trophic ulcers (133). The effect of NGF on human neurotrophic 
corneal ulcer is mediated by high affinity NGF, since the ocular 
surface express high-affinity NGFR (134). Specifically, NGFR 
have been found in basal epithelial cells and in stromal cells. 
These findings suggest therefore that NGF mediated its action 
through the proliferation and differentiation of corneal epithelial 
cells. The present data are in line with the current pathogenic 
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hypothesis for neurotrophic ulcer. It has been thought that 
corneal nerves release a trophic factor, absent or decreased in 
neurotrophic ulcer, which stimulates the corneal epithelium 
to heal. The finding that exogenous NGF restored corneal 
integrity and sensitivity suggests that the progressive corneal 
damage observed in some cases of keratitis associated with 
sensory nerve deficit could originate from a deficit of endog- 
enous NGF in the corneal microenvironment. This NGF defi- 
cit hypothesis is in agreement with the effects of this factor 
observed in other biological systems. Indeed, NGF treatment 
induces a prompt restoration of corneal ulcer, an absence of 
relapse of the disease and a persistence of corneal sensitivity 
without any local or systemic side effects. 
CONCLUSION 
We have briefly presented past and recent data supporting the 
hypothesis that in addition to its role as a neurotrophic regula- 
tor, NGF displays immunologic and hematological effects, and 
is involved in inflammatory responses. We have also presented 
and discussed current knowledge about the key role played by 
MC in these events. The studies on NGF-MC interaction led to 
Table 1. Nonneurological diseases and basal NGF alteration 
Humans 
Kawasaki disease 
Giant cell arteritis* 





















: NGF and mast cells are correlatively 
studied. 
the observation that allergic responses in humans are also 
characterized by the release into the bloodstream of NGF and 
that Th-2 cells, which play a pivotal role in allergy, are NGF 
responsive and NGF-producing cells (25,113). Most, if not all 
available data on the nervous system indicated that NGF is in- 
volved either in preventing or reducing the neuronal damages 
both in developing and mature nerve cells. There is evidence in 
animal models, however, that NGF through its effect on 
neuropetide synthesis and release, enhances hyperalgesia and 
inflammatory responses. It should be mentioned that to induce 
hyperalgesia in humans, higher levels of NGF than those 
observed in allergy patients are required (38). However, injec- 
tion of highly purified NGF does not induce joint inflammation 
(92). Nonetheless, the possibility that high levels of NGF can 
induce undesired effects cannot be excluded. Altogether, the 
current data favors the hypothesis of a regulatory role of NGF 
on cells of the immune system. Additional investigations into 
the different types of allergic responses and changes in basal 
NGF levels may also provide a better understanding of the NGF 
role in the mechanisms involved in allergic and/or inflammatory 
diseases. Table 1 presents a selected list of NGF-related non- 
neurological diseases. 
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